Most Adults 50+ Would Get Dementia Vaccine
A USC Schaeffer Center survey found 72% of adults 50 and older would likely or definitely take a hypothetical dementia vaccine.
Live Poll
Would you get a vaccine that cut your dementia risk by half?
U.S. Alzheimer's News
This section covers Alzheimer's disease and dementia in the United States — research advances, treatment approvals, caregiving and the public health dimensions of a condition that affects a growing share of the aging population. Reporting follows the science and the systems built around it.
Recent news
November 7, 2026
Human Brain Tissue Grows in Mice, Study ShowsStanford researchers transplanted lab-grown human brain organoids into genetically modified mice that lacked most of their cerebral cortex and hippocampus.
November 7, 2026
Henry Winkler Discusses Decade of TherapyThe 81-year-old actor described his therapy journey during an appearance on The Drew Barrymore Show.
November 7, 2026
Sinise Shares Son's Cancer Fight at Reagan LibraryActor Gary Sinise discussed his upcoming memoir about his son Mac's battle with a rare bone cancer during a Reagan Library appearance.
November 6, 2026
ADHD Drugs Show Promise for Perimenopause Brain FogA systematic review presented at The Menopause Society meeting found ADHD medications may improve executive function during perimenopause.
November 6, 2026
Larsa Pippen Discloses Brain Aneurysm DiagnosisThe reality star shared news of her diagnosis on Instagram, days after Matt Damon revealed his wife had undergone brain surgery for an aneurysm.
November 6, 2026
Digital Program Eases Chinese-American Dementia CaregivingA seven-week mobile support program improved positive caregiving experiences among Chinese-American dementia caregivers in a pilot study.
November 5, 2026
Pat Summitt Foundation Releases Alzheimer's ReportThe foundation marked its 15th anniversary while unveiling new findings and a plan to support patients and caregivers.
November 5, 2026
FDA Flags Vanda's Nereus Ad as MisleadingThe agency says the animated TV spot misstates the drug's safety and effectiveness and must be answered in writing within 15 working days.
November 5, 2026
Gain Therapeutics to Present Parkinson's PostersThe biotech company will share two late-breaking posters at a Milan congress and a separate preclinical poster at Neuroscience 2026 in Washington.
November 5, 2026
AAN Launches Year-End Campaign for Brain ResearchThe American Academy of Neurology is asking donors to support its research program as demand for funding outpaces available resources.
More in Alzheimer’s
Drug approval decisions and the clinical trial data behind them, research findings on risk factors and prevention strategies, caregiver burden data and the policy and support infrastructure available to families, and early detection and diagnostic technology developments are the recurring subjects in this coverage. New York, Los Angeles, Chicago, Houston and Phoenix are home to major neurology research centers and memory care systems whose findings and capacity affect national coverage of how the disease is being addressed at scale. Drug approvals in this area have generated some of the most complex and debated coverage of any recent regulatory decision, as questions about clinical evidence, cost and prescribing criteria have extended the story well beyond the approval announcement itself. Caregiver burden has emerged as an increasingly prominent subject alongside the clinical coverage, as the scale of unpaid family caregiving for people with dementia has become more visible in both research and policy discussions.